©The Author(s) 2024.
World J Gastrointest Surg. Oct 27, 2024; 16(10): 3224-3238
Published online Oct 27, 2024. doi: 10.4240/wjgs.v16.i10.3224
Published online Oct 27, 2024. doi: 10.4240/wjgs.v16.i10.3224
Table 1 Basic patient characteristics and short-term efficacy, n (%)
| Variables | Total (n = 219) | P-SOX (n = 149) | SOX (n = 70) | Z | P value |
| Age | 2.674 | 0.102 | |||
| ≤ 60 | 142 (64.8) | 102 (68.5) | 40 (57.1) | ||
| > 60 | 77 (35.2) | 47 (31.5) | 30 (42.9) | ||
| Sex | 0.514 | 0.473 | |||
| Male | 184 (84) | 127 (85.2) | 57 (81.4) | ||
| Female | 35 (16) | 22 (14.8) | 13 (18.6) | ||
| BMI | 0.278 | 0.598 | |||
| 18.5–24 | 140 (63.9) | 97 (65.1) | 43 (61.4) | ||
| < 18.5 or > 24 | 79 (36.1) | 52 (34.9) | 27 (38.6) | ||
| ASA | 0.168 | 0.681 | |||
| 1+2 | 178 (81.3) | 120 (80.5) | 58 (82.9) | ||
| 3 | 41 (18.7) | 29 (19.5) | 12 (17.1) | ||
| RECIST 1.1 | 1.906 | 0.167 | |||
| Ineffective | 104 (47.5) | 66 (44.3) | 38 (54.3) | ||
| Effective | 115 (52.5) | 83 (55.7) | 32 (45.7) | ||
| TRG | 1.324 | 0.250 | |||
| Effective | 128 (58.4) | 91 (61.1) | 37 (52.9) | ||
| Ineffective | 91 (41.6) | 58 (38.9) | 33 (47.1) | ||
| Tumor location | 0.260 | 0.878 | |||
| Lower | 76 (34.7) | 51 (34.2) | 25 (35.7) | ||
| Upper | 69 (31.5) | 46 (30.9) | 23 (32.9) | ||
| Middle | 74 (33.8) | 52 (34.9) | 22 (31.4) | ||
| Differentiation | 1.883 | 0.390 | |||
| Poorly | 101 (46.1) | 64 (43) | 37 (52.9) | ||
| Moderate | 72 (32.9) | 52 (34.9) | 20 (28.6) | ||
| Well | 46 (21) | 33 (22.1) | 13 (18.6) | ||
| cT stage | 0.384 | 0.825 | |||
| 2 | 60 (27.4) | 42 (28.2) | 18 (25.7) | ||
| 3 | 117 (53.4) | 80 (53.7) | 37 (52.9) | ||
| 4 | 42 (19.2) | 27 (18.1) | 15 (21.4) | ||
| cN stage | 0.155 | 0.694 | |||
| Negative | 76 (34.7) | 53 (35.6) | 23 (32.9) | ||
| Positive | 143 (65.3) | 96 (64.4) | 47 (67.1) | ||
| cTNM1 | 1.170 | 0.557 | |||
| II | 120 (54.8) | 83 (55.7) | 37 (52.9) | ||
| III | 52 (23.7) | 37 (24.8) | 15 (21.4) | ||
| IV | 47 (21.5) | 29 (19.5) | 18 (25.7) | ||
| Tumor diameter | 2.196 | 0.333 | |||
| ≤ 2 | 55 (25.1) | 33 (22.1) | 22 (31.4) | ||
| 2-5 | 91 (41.6) | 64 (43) | 27 (38.6) | ||
| ≥ 5 | 73 (33.3) | 52 (34.9) | 21 (30) | ||
| Laurnen | 3.274 | 0.195 | |||
| Enteric | 42 (19.2) | 29 (19.5) | 13 (18.6) | ||
| Mixed type | 98 (44.7) | 72 (48.3) | 26 (37.1) | ||
| Diffuse | 79 (36.1) | 48 (32.2) | 31 (44.3) | ||
- Citation: Wang YC, Feng L, Wang GP, Yu PJ, Guo C, Cai BJ, Song Y, Pan T, Lin BH, Li YD, Xiao JJ. Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer. World J Gastrointest Surg 2024; 16(10): 3224-3238
- URL: https://www.wjgnet.com/1948-9366/full/v16/i10/3224.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i10.3224